Low Dose Rapamycin for RA control disease activity without overtreatment, J Immunol Res. 2019

Jonas · 2024-01-16T01:54:26.866Z

Rapamycin and RA: Low-dose sirolimus immunoregulatory therapy selectively upregulated Tregs and partly replaced the usage of immunosuppressants to control disease activity without overtreatment and evaluable side effects (J Immunol Res. 2019)

Screenshot 2024-01-15 at 5.43.34 PM1482×938 81 KB

PubMed Central (PMC)

Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active...

We have reported previously the insufficient absolute number or functional defects of regulatory T cells (Tregs) in patients with rheumatoid arthritis (RA), challenging conventional unspecific immunosuppressive therapy. Sirolimus, a mTOR inhibitor,...

Screenshot 2024-01-15 at 5.55.08 PM1620×270 54.5 KB

Neo · 2024-01-16T03:53:19.681Z

sirolimus at a dosage of 0.5 mg on alternate days for 24 weeks